Copy Link Print Information

Cabotegravir sodium

(Synonyms: GSK-1265744 sodium; S/GSK1265744 sodium)
14 Cited Publications
Customer Review

Based on 14 publication(s) in Google Scholar

Cabotegravir (GSK-1265744) sodium is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir sodium can be used to research AIDS.

For research use only. We do not sell to patients.

  • Purity: 99.87%
  • CAS No.: 1051375-13-3
  • Formula: C19H16F2N3NaO5
  • Molecular Weight:427.33
  • Storage:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Cabotegravir sodium Chemical Structure
    Cabotegravir sodium Chemical Structure
  • Experimental Validation Results for Cabotegravir sodium
  • Experimental Validation Results for Cabotegravir sodium
  • Experimental Validation Results for Cabotegravir sodium
  • Experimental Validation Results for Cabotegravir sodium
  • Experimental Validation Results for Cabotegravir sodium
CAS No.: 1051375-13-3
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Cabotegravir sodium:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Cabotegravir sodium

More
Customer Validation & Images
In Vivo Efficacy StudyFlow CytometryCell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • Flow Cytometry
  • Flow Cytometry
  • Cell Proliferation/Viability Assay

All HIV Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Cabotegravir sodium Chemical Structure
    Cabotegravir sodium Chemical Structure
    1/16
  • 1/16

    Cabotegravir sodium purchased from MedChemExpress. Usage Cited in: J Infect Dis. 2025 Jul 15:jiaf362. [Abstract]

    Customer Validation
     Cabotegravir (CAB, 5.0mg/kg, administered via oral gavage daily). The viability rate is depicted.

  • 1/16

    Cabotegravir sodium purchased from MedChemExpress. Usage Cited in: J Infect Dis. 2025 Jul 15:jiaf362. [Abstract]

    Customer Validation
     Cabotegravir (CAB, 5.0mg/kg, administered via oral gavage daily). Dam litter size and percent increase in maternal weight normalized to litter size.

  • 1/16

    Cabotegravir sodium purchased from MedChemExpress. Usage Cited in: J Infect Dis. 2025 Jul 15:jiaf362. [Abstract]

    Customer Validation
     Cabotegravir (CAB, 5.0 mg/kg, gavage once daily). Representative SSEA3 + flow plot of DTG dose response in CA1S hESCs compared with the fluorescence minus 1 (FMO) and 0.1% DMSO controls; vertical line denotes SSEA-3 positivity.

  • 1/16

    Cabotegravir sodium purchased from MedChemExpress. Usage Cited in: J Infect Dis. 2022 Nov 28;226(11):1992-2001. [Abstract]

    Customer Validation
     Exposure to bictegravir (BIC)-, Cabotegravir (CAB, 5.0 mg/kg, gavage once daily)-, and dolutegravir (DTG)-containing combination antiretroviral therapy (cART) results in loss of pluripotency markers. SSEA-3+ and TRA-1-60+ expression normalized to corresponding 0.1% dimethyl sulfoxide (DMSO) vehicle controls (dashed lines), after exposure to no treatment (culture media without 0.1% DMSO, Ø), or 1× Cmax (unless indicated) cART regimens, in CA1S (left, n = 5) and H9 (right, n = 6, with an additional n = 4 at 0.5× Cmax) cells, respectively. Data collected via flow cytometry.

  • 1/16

    Cabotegravir sodium purchased from MedChemExpress. Usage Cited in: J Infect Dis. 2022 Nov 28;226(11):1992-2001. [Abstract]

    Customer Validation
     Bictegravir (BIC), Cabotegravir (CAB, 5.0 mg/kg, gavage once daily), and dolutegravir (DTG) human embryonic stem cell (hESC) toxicity and differentiation occur in a dose-dependent manner. Live cell count, viability, apoptosis normalized to 0.1% dimethyl sulfoxide (DMSO) control in CA1S (left, n = 3) and H9 (right, n = 6) hESCs treated with 5 (4 in H9) different integrase strand transfer inhibitors at various doses for 3.5 days.

  • Cabotegravir sodium